Shana Novak Stone Gety pictures
President Donald Trump is sharp Definitions In Canada, Mexico and China may exacerbate the lack of drugs in the United States, increase the healthcare costs of patients and threaten public drug makers with financial distress.
Trump announced on Saturday that it will impose a 25 % tariff on all the goods that are being charged from Canada and Mexico almost and 10 % responsibility on imports from China, which were all accelerated on Tuesday. On Monday, Mexico President Claudia Xinbum Bardo said that the United States would take place Delay the proposed definitions In the country for one month after Mexico approval Promotion of security On its borders.
Trump said that the definitions will remain in place until the three countries stop the flow of fentanel and immigrants who are not documented in the United States
But import taxes come at a time when the United States is struggling with unprecedented Decreased decisive medicine that ranges One of the injection cancer treatments to holidays, or cheaper versions of branded drugs, which forced hospitals and patients to medicines. It also comes as many Americans are struggling to provide the costs of high medications for prescribed medications.
US It adopts heavily Other countries of pharmaceutical products, especially for public medicines. Those medicines It constitutes 90 % Of the recipes of Americans, so the customs tariff can threaten the access of many patients to reasonable treatments.
China in particular is a great resource for active pharmaceutical components, or application programming facades, for both brand and public drugs due to low manufacturing costs in the country. Application interfaces are the main component of a drug that causes the effect required for treatment. Some general medications are fully manufactured.
The definitions of drug lack can be already formed by forcing public manufacturers to get out of the market due to low profit margins, according to statement From John Murphy, CEO of the Accessible Medicines Association, which represents public pharmaceutical companies.
“Generally manufacturers cannot simply accommodate new costs,” Murphy said on Sunday. “We sell our manufacturers at a very low price, sometimes confused, and they are increasingly forced out of the market where you are underwater.”
The Trump administration urged the exemption of public products from the customs tariff, adding that the total value of all public sales in the United States has decreased by $ 6.4 billion in five years despite “growth in size” and the launch of new public medicines.
The Health Care Distribution Alliance, which represents 40 drug distributors, also called for a reconsideration of the Trump administration, including pharmaceutical products in definitions. In a statement on Sunday, the group said that the customs tariff will strive the pharmaceutical supply chain and “can negatively affect American patients”, whether by increasing the costs of medical products or manufacturers that leave the market.
The group said that the customs tariff will put additional pressure on an industry in financial distress, noting that the distributors are only 0.3 % low profit margins.
The United States is likely to see a “new and double shortage of important drugs”, and these costs will be transferred to motivated and patients, including Medicare and Medicaid programs, “said the Health Care Distribution Alliance.
and appreciation From the Budget Laboratory at Yale University, the prices of long -term pharmaceutical products in the United States will be 1.1 % higher after the shifts in the supply chain.
Pharmaceutical research and manufacturers in America, which represents pharmaceutical companies, said in a statement that it is participating in Trump's goal in ensuring that it maintains its “global leadership in pharmaceutical innovation and manufacturing.”
The group added that commercial measures should focus on “addressing unfair practices abroad and protecting our intellectual property.”
Medical devices
The United States also depends on manufacturing abroad for medical devices, where many major components and final products are obtained from countries such as China, Mexico and India.
For example, Intuitive surgical,, Which make automatic surgical systems, was revealed in the annual a report Last week, a “large majority” of the company's tools and accessories are manufactured in Mexicali, Mexico.
The company said that the customs tariff for the country “will increase the costs of our products manufactured in Mexico and negatively affect our total profit.”
Advamed, the largest medical devices association in the world, urged the Trump administration to exempt medical products from definitions. In a statement, the group said that import taxes can lead to a lack of critical medical techniques, the high prices of patients and motivations, and a lower degree of research and development.
Advamed said that the customs tariffs and the costs associated with it work mainly as a “tax tax”, noting that Trump provided a move in a large part of the medical technology sector when it imposed a tariff on China during his first term.
The customs tariff can also affect hospitals, which rely on imports for daily supplies, such as gowns, gloves, and injecting, along with larger elements such as X -ray equipment.
But the American Medicine Manufacturers Association, which calls for American companies that produce medical protection equipment, or personal protection equipment, supports definitions on China and increases local production of these products.
In a statement on Monday, the group said that the customs tariff realizes that China “has not changed its ways and continues to engage in anti -competition and dangerous behavior that harms the manufacturers of civilized equipment and medical supply and threatens supply chains and national security.”
During the epidemic, the American Medical Manufacturers Association accused China is to reduce the price of face masks to undermine American producers.
